HemaCare Corp.
15350 Sherman Way
Suite 423
Van Nuys
California
91406
United States
Tel: 877-310-0717
Fax: 818-251-5300
Website: https://www.hemacare.com
Email: mailroom@hemacare.com
86 articles about HemaCare Corp.
-
HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio
6/2/2020
Simplify complex study logistics with GMP-compliant cryopreserved leukopak for the development and commercialization of cell and gene therapies
-
Top Biopharma M&As in 2019
1/10/2020
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019. -
Charles River Laboratories Moves into Cell Therapies with $380 Million Acquisition of HemaCare
12/16/2019
Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash. -
HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate
11/19/2019
Advancing cell and gene therapies with the highest quality GMP-compliant bone marrow starting material
-
HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State Samples
3/28/2019
Advancing discoveries by providing scientists with high-quality disease-state biospecimens to support preclinical and clinical research
-
HemaCare Reports Full Year 2018 Results
3/26/2019
HemaCare Corporation announced operational highlights and financial results for the year ended December 31, 2018.
-
HemaCare to Chair and Present at Phacilitate Leaders World Supply Chain Panel Discussion
1/15/2019
HemaCare’s Global Head of Cell Therapy speaking at 1:30 pm EST on January 23, 2019
-
HemaCare Relocates Global Headquarters
12/6/2018
HemaCare Corporation today announced the company has moved its global headquarters to Northridge, California.
-
HemaCare Provides Starting Material for Three FDA Approved Cellular Therapies
11/14/2018
HemaCare Corp. (OTCMKTS: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces their involvement as a provider of leukapheresis process development material for 100% of the current FDA-approved immunocellular therapies, Kymriah® (Novartis; Switzerland), Yescarta® (Kite, a Gilead Company; CA, USA), and Provenge® (Dendreon; WA, USA).
-
HemaCare Reports First Half 2018 Results
8/21/2018
HemaCare Corporation announced operational highlights and financial results for the six months ended June 30, 2018.
-
HemaCare Expands Development of Cellular Therapy Services by Bolstering Scientific Team with Two Strategic New Hires
7/17/2018
Industry mavens strengthen HemaCare’s expertise in cell therapy and bioprocessing
-
HemaCare Reports Full Year 2017 Results
3/8/2018
HemaCare Corporation announced operational highlights and financial results for the year ended December 31, 2017.
-
HemaCare and Charles River Laboratories Announce Strategic Partnership to Accelerate Drug Discovery and Development
2/6/2018
HemaCare and Charles River Laboratories have formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice.
-
HemaCare Announces OneBlood Exercises Second Investment Tranche Option
1/8/2018
Under the terms of the agreement signed January 6, 2017, OneBlood is purchasing an additional 363,786 shares at $3.44 per share.
-
HemaCare Plays Mission Critical Role in Global Cellular Therapy Development
9/12/2017
-
HemaCare Reports Strong First Half 2017 Results
8/21/2017
-
HemaCare Inks Lease for New HQ Relocation and Expansion
7/24/2017
-
HemaCare Corp. Announces Expansion Of Disease State Cells For Bioresearch
7/17/2017
-
HemaCare Corp. Attends AACR Annual Meeting
3/27/2017
-
HemaCare Corp. Reports Strong, Profitable 2016 Results
3/13/2017